The marketing authorisation for Recuvyra has expired following the marketing-authorisation holder’s decision not to apply for a renewal.
Recuvyra : EPAR - Summary for the public (PDF/513.7 KB)
First published: 12/10/2011
Last updated: 12/07/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Eli Lilly and Company Limited
|Date of issue of marketing authorisation valid throughout the European Union||
13/10/2016 Recuvyra - EMEA/V/C/002239 - IB/0009/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
For the control of pain associated with orthopaedic and soft tissue surgery in dogs.